PDCD1 and metastatic melanoma: Ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and nivolumab and pembrolizumab, which are inhibitors of programmed cell death protein-1 (PD-1), were approved by Food and Drug Administration (FDA) to treat metastatic melanoma.